Key Insights

Highlights

Success Rate

90% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

1.9%

1 terminated out of 53 trials

Success Rate

90.0%

+3.5% vs benchmark

Late-Stage Pipeline

9%

5 trials in Phase 3/4

Results Transparency

0%

0 of 9 completed with results

Key Signals

90% success

Data Visualizations

Phase Distribution

39Total
Not Applicable (8)
P 1 (3)
P 2 (23)
P 3 (5)

Trial Status

Recruiting23
Unknown13
Completed9
Not Yet Recruiting5
Active Not Recruiting2
Terminated1

Trial Success Rate

90.0%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (53)

Showing 20 of 20 trials
NCT07177794Phase 3Recruiting

Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC

NCT07404228Not Yet Recruiting

Multidimensional Study Designed to Develop a Methodological Framework Based on MRI Data to Predict Pathological Complete Response (pCR) in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Treatment

NCT06719700Phase 2Recruiting

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

NCT07290972Recruiting

Compliance to Cervical Cancer Chemoradiation Guidelines: A Multicentric Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India

NCT07293013Not ApplicableRecruiting

A Study on the Effectiveness of Olive Oil Mouthwash in Alleviating Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer.

NCT07205536Phase 2Recruiting

Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy

NCT07235306Phase 2Not Yet Recruiting

Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC

NCT07086469Phase 2Recruiting

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

NCT07198165Phase 2Recruiting

SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC

NCT07131670Recruiting

Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes

NCT07091305Phase 2Active Not Recruiting

A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

NCT05161572Phase 2Terminated

Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer

NCT06219083Recruiting

Nutritional Status and Clinical Outcomes in Patients With Common Malignancies(NCOM)

NCT06421376Phase 2Recruiting

Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer

NCT04821765Phase 2Completed

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

NCT06156514Phase 3Recruiting

Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer

NCT06984289Completed

US Radiomics in Advanced Cervical Cancer

NCT06833801Not ApplicableNot Yet Recruiting

Application of Intelligent Care Systems in Radiation Therapy: Enhancing Patient Safety and Reducing Anxiety Through System Optimization and Real-Time Blood Data Monitoring

NCT04696757Phase 2Completed

Non-OpeRative MANagement of Rectal Cancer Patients

NCT06758830Phase 2Recruiting

Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.

Scroll to load more

Research Network

Activity Timeline